Antibiotic resistance of Helicobacter pylori in the Peruvian population: a systematic review and meta-analysis of its prevalence in the general population
DOI:
https://doi.org/10.47892/rgp.2022.423.1403Keywords:
Helicobacter pylori, Antibiotic resistance, Bacterial infection, PerùAbstract
Helicobacter pylori infection is quite common worldwide and is associated with gastric adenocarcinoma. The high rates of resistance found in Latin American countries justify the investigation of local resistance rates, which could improve the therapeutic approach and eradication rates. The objective is to evaluate the prevalence of resistance in Peru of Helicobacter pylori to commonly used antibiotics. All studies in the Peruvian population that revealed rates of antibiotic resistance of Helicobacter pylori were included. A systematic literature search was conducted up to January 2021, using PubMed and other databases. For the group of patient studies with the EUCAST cut-off point, the resistance was as follows: Amoxicillin 14% (95% CI: 6-25), Clarithromycin 43% (95% CI: 30-57), Metronidazole 58% (95% CI: 22-90) and 51% Quinolones (95% CI: 38-64). For the EUCAST cut-off group of sample studies, the following: Amoxicillin 57% (95% CI: 51-63), Clarithromycin 35% (95% CI 30-41), Metronidazole 67% (95% CI: 62-72) and 4% Tetracycline (95% CI: 2-7). A high antibiotic resistance of Helicobacter pylori was found in most of the groups studied, although with heterogeneity between the studies. The rate of resistance to tetracyclines was low and the studies were shown to be homogeneous.
Downloads
Metrics
References
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 175-86.
Curado, M. P., de Oliveira (2019). Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: A systematic review and meta-analysis. Cancer
epidemiology, 60, 141–148.
Castillo Contreras O, et al. Prevalencia de Helicobacter pylori en pacientes sintomáticos de consulta externa de la Red Rebagliati (EsSalud), Lima, Perú, en el período 2010-2013. Rev Gastroenterol Perú. 2016;36(1):49-55.
Escala Perez-Reyes AY, et al. ¿Cómo manejan la infección por Helicobacter pylori los médicos gastroenterólogos del Perú? Estudio basado en una encuesta realizada en el 2014. Rev Gastroenterol Peru. 2015;35(4): 295-305.
Pareja Cruz A, Navarrete Mejía PJ, et al. Seroprevalencia de infección por Helicobacter pylori en población adulta de Lima, Perú 2017. Horizonte Médico. 2017;17(2):55-8.
David, Consuelo, S., & Iván, J. (2014). Antibiotic Resistance of Helicobacter pyloriin Latin America and the Caribbean. Revista Colombiana de Gastroenterologia,29(3),218–227.
Guzmán J, Castillo D, et al. Susceptibilidad antimicrobiana y mutaciones en el gen ARNr 23s de Helicobacter pylori en pacientes dispépticos. Rev Peru Med Exp Salud Pública. 2019;36(2):270-4.
Globocan 2018 - Home [Internet]. [citado 27 de Octubre de 2020]. Disponible en:https:// gco.iarc.fr/today/data/factsheets/populations/604-peru-fact-sheets.pdf
Hoy D, Brooks P, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65: 934e9.
Brignardello-Petersen, R., et al. (2018). Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. Journal of Clinical Epidemiology, 93, 36–44.
Vasquez, A., Valdez, Y., et al. (1996). Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayetano Heredia and the Johns Hopkins University. Journal of clinical microbiology, 34(5), 1232–1234.
Berg, D. E., et al. (1997). Helicobacter pylori populations in Peruvian patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 25(5), 996–1002.
Soto, G., et al(2003). Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. The Journal of infectious diseases, 188(9), 1263–1275.
Mochizuki Tamayo, et al. (2011). Determinación de la susceptibilidad de cepas de Helicobacter pylori a Levofloxacino en formato pequeño y método de difusión en disco usando Agar yema de huevo. Revista de Gastroenterología del Perú, 31(3), 224-229.
Valdivieso M, et al. Clinical, epidemiologic, and genomic studies (SWOG S1119) of Helicobacter pylori in Lima, Peru: role of contaminated water. J Cancerol. 2016;3(2):52–63.
Boehnke, K. F., et al. (2017). Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. Infection and drug resistance, 10, 85–90.
Herdert Martín Albán Olaya, et al. (2018). Incidencia de resistencia a tratamiento convencional de Helicobacter pylori, en una población adulta de Cajamarca. Revista Caxamarca, 17(1-2).
Bilgilier, C., et al. (2020). Antimicrobial Resistance of Helicobacter pylori in Gastric Biopsy Samples from Lima/Peru. Microbial drug resistance (Larchmont, N.Y.), 10.1089/ mdr.2020.0241.
Reyes, L., & Erika, L. (2018). Tasa de Erradicación y Resistencia al Tratamiento para Infección Por Helicobacter pylori en pacientes del Hospital Apoyo-Pichanaki en el Año 2018. Uroosevelt.edu.pe.
Mendoza, C. (2021). Caracterización molecular de la resistencia antimicrobiana de Helicobacter pylori en pacientes dispépticos del Hospital y la Clínica Médica Cayetano Heredia. Upch.edu.pe
Gisbert JP, et al. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol. 2016 Dec;39(10):697-721. English, Spanish. doi: 10.1016/ j.gastrohep.2016.05.003. Epub 2016 Jun 21. Erratum in: Gastroenterol Hepatol. 2017 May;40(5):378.
Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin North Am 2011;21:613–635.
Cheung J, et al. Prevalence of Helicobacter pylori and antibiotic resistance in an aboriginal population in Canada’s arctic: preliminary results from the Aklavik H. pylori project (abstr M1058). Gastroenterology 2009;136:A341.
Martínez M, et al. (2014). Resistencia antibiótica del Helicobacter pylori en América Latina y el Caribe. Revista Colombiana de Gastroenterologia, 29(3), 218-227.
Vásquez A, et al. Metronidazole and Clarithromycin Resistance in Helicobacter pylori Determinate by measuring MICs of antimicrobial agents in color indicator egg yolk Agar in a miniwell format. J Clin Microbiology 1996; 34: 1232-1234.
Megraud FH. Pylori antibiotic resistance: Prevalence, Importance, and advances in testing. GUT 2004; 53: 1374-1384.
Fallone, C. A., et al(2016). The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology, 151(1), 51–69.e14.
Savoldi A, et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):1372-1382.e17.
Agudo S, et al. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid. Spain. J Clin Microbiol 2010;48:3703–3707.
Crowe SE. Helicobacter pylori Infection. N Engl J Med 2019; 380:1158.
Luther J, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105:65.
Venerito M, et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013;88:33–45.
Liao J, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18:373–377
Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin
Microbiol Infect Dis 1992; 11:777.
Mégraud F, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43:2747.
Malfertheiner P , Bazzoli F , Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus
clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial . Lancet 2011 ; 377 : 905 – 13.
Camargo MC, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109(4):485-95.
Downloads
Published
How to Cite
Issue
Section
License
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
2022 